Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
Program Halt Seen As 'Hit' To Vaccine-Making Reputation
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
You may also be interested in...
‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
Despite having multiple world-class pharma companies and innovative research, Japan is notably absent as a source of candidate vaccines for the coronavirus. The pandemic is again throwing into sharp relief past and present challenges around the country's vaccines sector.